<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560976</url>
  </required_header>
  <id_info>
    <org_study_id>sor419105ctil</org_study_id>
    <nct_id>NCT00560976</nct_id>
  </id_info>
  <brief_title>Serum NGAL Levels in Hemodialysis (HD) Patients; Relation to Iron Status, HD and Intravenous (IV) Iron Administration</brief_title>
  <official_title>Serum Neutrophil Gelatinase Associated Lipocalin (NGAL) Levels in Hemodialysis (HD) Patients; Relation to Iron Status, Hemodialysis, and Intravenous (IV) Iron Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess changes in serum levels of the siderophore binding
      protein NGAL by hemodialysis without and with intravenous iron administration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum and urine levels of the siderophore binding protein neutrophil gelatinase associated
      lipocalin (NGAL) are increased in a number of renal diseases, but has not been evaluated yet
      in dialysis patients. Since NGAL is suggested to be related to inflammatory processes and
      iron homeostasis, which are a major problem in dialysis patients, this study aims to assess
      the relation of serum NGAL levels in hemodialysis (HD) patients to iron status, inflammation,
      hemodialysis and intravenous(IV) iron administration. Our hypothesis is that serum NGAL
      levels in HD patients are related to iron status and inflammation and may change following
      hemodialysis and/or acute or chronic IV iron administration.

      The Specific aims are:

        1. To assess the relations between basal serum NGAL levels to iron, dialysis, and
           inflammation related parameters.

        2. To assess the effect of HD on serum NGAL levels and their relation with with iron,
           dialysis and inflammation related parameters.

        3. To assess the effects of weekly 100 mg IV iron in the first hour of HD on serum NGAL
           levels, and the relation of pre IV iron serum NGAL levels with iron, oxidative stress
           and inflammation related parameters. These assessments will be performed in the first
           weekly HD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2005</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CRP (C-Reactive Protein) and AOPP (Advanced Oxidative Protein Products) Levels</measure>
    <time_frame>To assess the effects of 100 mg IV iron in the first hour of the first weekly HD on the relation of pre IV iron serum NGAL levels with oxidative stress and inflammation related parameters.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Renal Failure Chronic Requiring Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Iron Saccharate (Venofer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Iron Saccharate (Venofer)100 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Saccharate (Venofer)</intervention_name>
    <description>Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).</description>
    <arm_group_label>Iron Saccharate (Venofer)</arm_group_label>
    <other_name>Ferric gluconate (Ferrlecit)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hemodialysis patients

        Exclusion Criteria:

          -  Acute disease (infection, thrombosis, ischemia, bleeding)

          -  Hepatitis B, Hepatitis C or HIV

          -  Intravenous iron administration or packed red cell transfusion in the last 4 weeks
             prior to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Tovbin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Tovbin, MD</last_name>
    <phone>972-54-296579</phone>
    <email>dtovbin@bgu.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nephrology, Soroka University Medical center</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Bnai-zion Medical Center,Nephrology,</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Biro, MD</last_name>
      <phone>97235028285</phone>
      <email>abiro@wolfson.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Katzir Zeev, MD</last_name>
      <phone>97235028291</phone>
      <email>Katzir@wolfson.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Biro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>April 17, 2013</last_update_submitted>
  <last_update_submitted_qc>April 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soroka University Medical Center</investigator_affiliation>
    <investigator_full_name>David Tovbin</investigator_full_name>
    <investigator_title>Dr David Tovbin, Department of Nephrology</investigator_title>
  </responsible_party>
  <keyword>neutrophil gelatinase associated lipocalin</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>iron</keyword>
  <keyword>inflammation</keyword>
  <keyword>Oxidative Stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric gluconate</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

